GlobeNewswire·Jul 28, 2026, 7:30 AM ET

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

Kazia Therapeutics filed a provisional patent application for a novel strategy to prevent metastatic recurrence in high-risk early-stage triple-negative breast cancer (TNBC).
Preclinical findings from a high-risk early-stage TNBC model showed that adding paxalisib to standard neoadjuvant chemotherapy, anti-PD-1 immunotherapy, and surgery reduced residual disease and local recurrence by 95% while lowering lung metastatic burden by 40%.
Ex vivo studies on patient tumor samples revealed that paxalisib completely disrupted 100% of circulating tumor cell clusters.
The strategy targets biological programs allowing surviving cells to evade immune surveillance, rather than solely focusing on killing tumor cells.
Current clinical development includes an ongoing Phase Ib study of paxalisib with pembrolizumab and chemotherapy in advanced metastatic TNBC, which showed preliminary objective tumor responses and CTC cluster disruption.
Kazia is actively evaluating opportunities to broaden paxalisib's clinical development into earlier-stage TNBC based on the convergence of preclinical and translational data.
Paxalisib is an investigational brain-penetrant PI3K/Akt/mTOR pathway inhibitor licensed from Genentech, with prior Orphan Drug and Fast Track Designations granted by the FDA for glioblastoma and other indications.